![](https://cmgsites.s3.us-west-1.amazonaws.com/eyeclinicofaustin.com/wp-content/uploads/2014/02/01210346/image_2019_12_24T07_25_22_951Z-1200x809.png)
Rho kinase inhibitors are a new class of glaucoma drugs currently in clinical trials. Rho kinase (dubbed “ROCK”) inhibitors promise to act specifically on the eye’s drainage canals (called the trabecular meshwork) a main outflow and blockage site in glaucoma.